Headlines about Acorda Therapeutics (NASDAQ:ACOR) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Acorda Therapeutics earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.2014511025547 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline – January 17, 2018 (finance.yahoo.com)
- EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 (finance.yahoo.com)
- Acorda Resubmits New Drug Application for INBRIJA™ (CVT-301, levodopa inhalation powder) (markets.financialcontent.com)
- Form 4 ACORDA THERAPEUTICS INC For: Dec 01 Filed by: Wasman Jane – StreetInsider.com (streetinsider.com)
- The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of Acorda Therapeutics, Inc … – Business Wire (press release) (businesswire.com)
ACOR has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, October 30th. Janney Montgomery Scott set a $17.00 target price on shares of Acorda Therapeutics and gave the stock a “hold” rating in a report on Thursday, November 16th. Stifel Nicolaus lowered shares of Acorda Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $26.00 to $15.00 in a report on Thursday, November 16th. J P Morgan Chase & Co dropped their target price on shares of Acorda Therapeutics to $19.00 and set a “neutral” rating for the company in a report on Wednesday, November 15th. Finally, Cowen reiterated a “buy” rating and set a $30.00 target price on shares of Acorda Therapeutics in a report on Friday, November 17th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $21.47.
Shares of Acorda Therapeutics (NASDAQ ACOR) opened at $20.75 on Friday. The company has a quick ratio of 2.40, a current ratio of 2.77 and a debt-to-equity ratio of 0.49. Acorda Therapeutics has a 1-year low of $13.60 and a 1-year high of $33.00.
Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The company had revenue of $141.07 million during the quarter, compared to analysts’ expectations of $150.64 million. During the same quarter last year, the business earned ($0.04) earnings per share. The business’s quarterly revenue was up 4.0% on a year-over-year basis. analysts expect that Acorda Therapeutics will post -0.07 EPS for the current fiscal year.
In other news, insider Burkhard Blank sold 11,050 shares of Acorda Therapeutics stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $20.53, for a total transaction of $226,856.50. Following the completion of the transaction, the insider now directly owns 33,150 shares in the company, valued at $680,569.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.90% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Acorda Therapeutics (ACOR) Share Price” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/12/08/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-acorda-therapeutics-acor-share-price.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.